

Table 3. Time Spent for Data Verification.

| | n | Mean (SD) | Median | Min – Max |
|--|-----|-----------|--------|------------|
| All | 110 | 7.1 (3.9) | 6.0 | 2.0 – 20.0 |
| Medium of source document | | | | |
| Electric health record | 64 | 7.7 (4.0) | 6.0 | 2.0 – 20.0 |
| Both electric health record and paper record | 32 | 6.6 (3.7) | 5.0 | 3.0 – 20.0 |
| Paper record | 14 | 5.4 (2.9) | 5.0 | 2.0 – 11.0 |
| Number of auditing staff to verify for each case | | | | |
| One staff | 71 | 8.0 (4.0) | 6.0 | 3.0 – 20.0 |
| Two staffs | 39 | 5.5 (3.0) | 5.0 | 2.0 – 15.0 |
| Number and proportion of agreement items for each case | | | | |
| 25 items (100%) | 29 | 6.9 (4.2) | 6.0 | 2.0 – 20.0 |
| 23-24 items (90% < 99%) | 36 | 5.9 (3.1) | 5.0 | 2.0 – 15.0 |
| 20-22 items (80 < 90%) | 33 | 8.3 (4.2) | 8.0 | 3.0 – 20.0 |
| <20 items (≤80%) | 12 | 7.8 (3.5) | 6.5 | 4.0 – 15.0 |

Abbreviation: SD, standard deviation.

Furthermore, in cases involving transfer to other facilities after surgery, completeness of the follow-up of survival information varied among the hospitals.

Time Spent for Data Verification

Median time for data verification per case was 6.0 minutes, ranging from 2.0 to 20.0 minutes (Table 3). Verification of paper-based records took a median of 5.0 minutes, while electronic and the combination of both types took 6.0 and 5.0 minutes, respectively ($P = .08$). Median time of verification was 6.0 minutes when one auditor conducted the verification, and 5.0 when both the auditors participated ($P < .05$). Concerning the degree of record accuracy per case, the median time in minutes was 6.0, 5.0, 8.0, and 6.5 for 100%, 90% to 99%, 80% to 90%, and ≤80%, respectively ($P < .05$).

Comment

Quality improvement initiatives need to be based on the scientific evidence generated from reliable and valid data. In this report, we demonstrated that the JCCVSD on pediatric cardiovascular surgeries achieved fairly complete registration of cases and accurate data collection of clinical information. Thus, this database could potentially be useful in improving the quality of care.

In regard to the completeness of registration, there were very few unregistered patients for the first operations in the same administration. Duplicated registration occurred mainly due to typing error and misassignment of unique patient ID. Such cases could have been avoided by fool-proof modification of data entry to display potential duplication if several essential variables (eg, ID, birth date, sex, and date of surgery) were identical. More fundamentally, however, a hospital's capacity to maintain operation logs and other clinical record documentation in an accountable and traceable fashion is essential. An interview with a data manager revealed that failed registration happened, because the site hospitals differently interpreted the registration criteria for subsequent operations during the same administration and arbitrarily decided whether such cases

should be registered as independent operation or operative complication for any reason after surgery. This underscores the importance of keeping data managers informed about the criteria for clarification. As such, validation could involve interactive processes between daily practice at the site hospitals and refinements of the registration system.

As to the accuracy of data, categorical information such as demographics showed a high proportion of consistency. Continuous variables presented a lower level of accuracy due to inconsistent use of rounding up, mistyping, and other technical reasons; however, the difference between the submitted data and the source documents was relatively small. Some clinical databases have adopted “acceptable range” for the judgment of data consistency for continuous variables.²¹ As such, the judgment rule of accuracy for continuous variables is a matter of debate in other databases.^{19,21} Training of data managers in each site hospital was also essential for accurate data collection through enhanced compliance with the definition of data items. The display design of entry form was another influential factor in avoiding entry errors. In this regard, the JCCVSD has some important factors to maintain high-quality data, such as nomination of the data manager in charge of securing data traceability, a fool-proof entry system that does not allow missing values for essential information, and organizing a meeting of data managers twice each year for continuous training.

Another characteristic of the JCCVSD is high accuracy in follow-up outcomes, especially the 90-day mortality after surgery, compared to other congenital databases,¹⁷ which warrants some discussion. Success of patient follow-up could be attributed to social environments specific to Japan, such as longer length of hospital stay, limited number of hospitals eligible for congenital heart surgery, and better accessibility to continuous treatment under universal coverage by public health insurance system.²²

When the activities of data audit expand, we should take serious account of efficiency in terms of cost and time. As we evaluated the time required for data verification, paper-based source and the number of auditors were significant factors to reduce the time. However, we have not yet determined how many auditors are most efficient in what conditions. Additionally,

the time for data verification can be affected by whether hospitals have standardized formats of medical records or not. The methodology of data verification of clinical databases remains to be systematically studied, and we acknowledge the need of further surveys to establish standardized and efficient mode of data verification in comparison with examples from other recommendations.²³ Appropriate size and method of sampling for validation is another important factor to determine efficiency as well as validity of audit. In this regard, the current data verification chose six hospitals in an ad hoc manner, which should be recognized as a study limitation.

The present study demonstrates the initial success of the JCCVSD in high-quality data collection for improvement in the quality of pediatric cardiovascular surgery. However, we are still challenged by some limitations for further improvements. First, hospitals adopted a variety of record formats for operation logs that seriously hindered standardized data collection and threatened the results of our assessment of registry completeness. This should be resolved through standardization of clinical information on operation logs based on the subspecialty consensus. Second, we found that the registration of adult cases with congenital heart conditions could be problematic, given that such a case may be inconsistently registered to the adult cardiovascular surgery database rather than pediatric database. This should also be solved by consensus building among the subspecialty circle. Third, as already mentioned, half of the hospitals we surveyed were selected randomly, but the rest were selected by request from the JCCVSD committee. Thus, there might be selection bias of hospitals. Furthermore, we did not calculate sample size for statistical power, which might have led to overlooking significant inconsistency. Fourth, we should add other important variables for data verification of clinical databases. For example, diagnosis, procedure, and outcomes (eg, postoperative complications) are important information as fundamental statistics in clinical databases. Assessment of accuracy in coding these variables with systematic method of verification will be required to assure quality of clinical database.

In summary, we conducted data verification of the JCCVSD and found that data of the JCCVSD in 2008 to 2009 exhibited high completeness of registration and accuracy of data entry. The initial success in quality assurance of the JCCVSD should be strengthened through further sophistication of registration protocol, continual training of data managers and auditors, and rigorous expansion of verification activities.

Acknowledgments

Authors would like to express appreciation to all people and academies who cooperated in the JCCVSD.

Declaration of Conflicting Interests

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Funding

The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: Data

verification activity of the JCCVSD was supported by the Japan Cardiovascular Surgery Database Organization.

References

1. Motomura N, Miyata H, Tsukihara H, Okada M, Takamoto S; Japan Cardiovascular Surgery Database Organization. First report on 30-day and operative mortality in risk model of isolated coronary artery bypass grafting in Japan. *Ann Thorac Surg.* 2008;86(6): 1866-1872.
2. Hall BL, Hamilton BH, Richards K, Bilimoria KY, Cohen ME, Ko CY. Does surgical quality improve in the American College of Surgeons National Surgical Quality Improvement Program: an evaluation of all participating hospitals. *Ann Surg.* 2009; 250(3): 363-376.
3. Jacobs JP, O'Brien SM, Pasquali SK, et al. Variation in outcomes for benchmark operations: an analysis of the Society of Thoracic Surgeons Congenital Heart Surgery Database. *Ann Thorac Surg.* 2011;92(6): 2184-2191; discussion 2191-2192.
4. Pasquali SK, Jacobs JP, Shook GJ, et al. Linking clinical registry data with administrative data using indirect identifiers: implementation and validation in the congenital heart surgery population. *Am Heart J.* 2010;160(6): 1099-1104.
5. Jacobs JP, Maruszewski B, Kurosawa H, et al. Congenital heart surgery databases around the world: do we need a global database? *Semin Thorac Cardiovasc Surg Pediatr Card Surg Annu.* 2010;13(1): 3-19.
6. Ong AT, Serruys PW, Mohr FW, et al. The SYNergy between percutaneous coronary intervention with TAXus and cardiac surgery (SYNTAX) study: design, rationale, and run-in phase. *Am Heart J.* 2006;151(6): 1194-1204.
7. Jacobs JP, Mavroudis C, Jacobs ML, et al. Nomenclature and databases—the past, the present, and the future: a primer for the congenital heart surgeon. *Pediatr Cardiol.* 2007;28(2): 105-115.
8. Herbert MA, Prince SL, Williams JL, Magee MJ, Mack MJ. Are unaudited records from an outcomes registry database accurate? *Ann Thorac Surg.* 2004;77(6): 1960-1964.
9. Elfström J, Stubberöd A, Troeng T. Patients not included in medical audit have a worse outcome than those included. *Int J Qual Health Care.* 1996;8(2): 153-157.
10. International Epidemiological Association (IEA) European Federation. Good Epidemiological Practice (GEP)-IEA Guidelines for proper conduct of epidemiological research; November 2007.
11. Theobald K, Capan M, Herbold M, Schinzel S, Hundt F. Quality assurance in non-interventional studies. *Ger Med Sci.* 2009;7: Doc29.
12. Whitney CW, Lind BK, Wahl PW. Quality assurance and quality control in longitudinal studies. *Epidemiol Rev.* 1998;20(1): 71-80.
13. International Conference on Harmonisation of technical requirements for registration of pharmaceuticals for human use. ICH Harmonised Tripartite Guideline For Good Clinical Practice E6(R1); 1996. <http://ichgcp.net/>. Accessed March 7, 2012.
14. Parkin DM, Bray F. Evaluation of data quality in the cancer registry principles and methods Part II. Completeness. *Eur J Cancer.* 2009;45(5): 756-764.

15. Arts DG, De Keizer NF, Scheffer GJ. Defining and improving data quality in medical registries: a literature review, case study, and generic framework. *J Am Med Inform Assoc.* 2002;9(6): 600-611.
16. The Society of Thoracic Surgeons. STS National Database. <http://www.sts.org/national-database>. Accessed March 7, 2012.
17. Clarke DR, Breen LS, Jacobs ML, et al. Verification of data in congenital cardiac surgery. *Cardiol Young.* 2008;18(suppl 2): 177-187.
18. National Cardiovascular Data Registry. National On-site Audit Program. <http://www.ncdr.com/webncdr/common/datacollection.aspx>. <http://jccvdsd.umin.jp/>. Accessed July 10, 2012.
19. Maruszewski B, Lacour-Gayet F, Monro JL, Keogh BE, Tobota Z, Kansy A. An attempt at data verification in the EACTS congenital database. *Eur J Cardiothorac Surg.* 2005;28(3): 400-404; discussion 405-406.
20. Japan Cardiovascular Surgery Database Organization. Japan Congenital Cardiovascular Database. <http://jccvdsd.umin.jp/>. Accessed March 7, 2012.
21. Shiloach M, Frencher SK Jr, Steeger JE, et al. Toward robust information: data quality and inter-rater reliability in the American College of Surgeons National Surgical Quality Improvement Program. *J Am Coll Surg.* 2010;210(1): 6-16.
22. Ikegami N, Yoo BK, Hashimoto H, et al. Japanese universal health coverage: evolution, achievements, and challenges. *Lancet.* 2011;378(9796): 1106-1115.
23. Tantsyura V, Grimes I, Mitchel J, et al. Risk-based source data verification approaches: pros and cons. *Drug Inform J.* 2010;44(6): 745-756.

Surgical results of reoperative tricuspid surgery: analysis from the Japan Cardiovascular Surgery Database[†]

Nobuhiro Umehara^{a,*}, Hiroaki Miyata^b, Noboru Motomura^b, Satoshi Saito^a and Kenji Yamazaki^a

^a Department of Cardiovascular Surgery, Tokyo Women's Medical University, Tokyo, Japan

^b Japan Cardiovascular Surgery Database Organization, Tokyo, Japan

* Corresponding author. Department of Cardiovascular Surgery, Tokyo Women's Medical University, Kawadacho 8-1, Shinjuku, Tokyo, Japan. Tel: +81-3-33538111; fax: +81-3-33560441; e-mail: sumehara@hij.twmu.ac.jp (N. Umehara).

Received 18 September 2013; received in revised form 14 February 2014; accepted 18 February 2014

Abstract

OBJECTIVES: Tricuspid valve insufficiency (TI) following cardiovascular surgery causes right-side heart failure and hepatic failure, which affect patient prognosis. Moreover, the benefits of reoperation for severe tricuspid insufficiency remain unclear. We investigated the surgical outcomes of reoperation in TI.

METHODS: From the Japan Cardiovascular Surgery Database (JACVSD), we extracted cases who underwent surgery for TI following cardiac surgery between January 2006 and December 2011. We analysed the surgical outcomes, specifically comparing tricuspid valve replacement (TVR) and tricuspid valve plasty (TVP).

RESULTS: Of the 167 722 surgical JACVSD registered cases, reoperative TI surgery occurred in 1771 cases, with 193 TVR cases and 1578 TVP cases. The age and sex distribution was 684 males and 1087 females, with an average age of 66.5 ± 10.8 years. The overall hospital mortality was 6.8% and was significantly higher in the TVR group than in the TVP group (14.5 vs 5.8%, respectively; $P < 0.001$). Incidences of dialysis, prolonged ventilation and heart block were also significantly higher in the TVR group than in the TVP group. Logistic regression analysis revealed that the risk factors of hospital mortality were older age, preoperative renal dysfunction, preoperative New York Heart Association Class 4, left ventricular dysfunction and TVR.

CONCLUSIONS: Surgical outcomes following reoperative tricuspid surgery were unsatisfactory. Although TVR is a last resort for non-repairable tricuspid lesions, it carries a significant risk of surgical mortality. Improving the patient's preoperative status and opting for TVP over TVR is necessary to improve the results of reoperative tricuspid surgery.

Keywords: Tricuspid valve • Reoperation • Database

INTRODUCTION

Tricuspid valve insufficiency (TI) following cardiovascular surgery causes right-sided heart failure and hepatic failure, which affect the prognosis [1, 2]. Tricuspid valve repair after cardiac surgery is less commonly performed than left-sided valve repair, and there are relatively few reports with small samples [3–5]. Thus, the outcomes of surgical intervention for severe tricuspid insufficiency remain unclear. The Japan Adult Cardiovascular Surgery Database (JACVSD) is a nationwide database established in 2000. The number of participating hospitals has gradually increased, and now, most hospitals performing cardiovascular surgeries have been enrolled. The Japan System for Cardiac Operative Risk Evaluation (Japan SCORE) is a risk model developed from JACVSD [6–8]. Therefore, we used JACVSD to examine the results of surgical treatment for TI following cardiac surgery. The objective of this

study is to analyse the surgical outcomes, specifically comparing tricuspid valve replacement (TVR) and tricuspid valve plasty (TVP).

MATERIALS AND METHODS

Study population

JACVSD was established to facilitate evaluation of surgical outcomes after cardiovascular procedures in centres throughout Japan. It currently captures clinical information from most Japanese hospitals. The data collection form has a total of 255 variables that are almost identical to those of the Society of Thoracic Surgeons' (STS) National Database [(definitions are available online at Websites: Japan Adult Cardiovascular Database. <http://www.jacvds.umin.jp>) (The Society of Thoracic Surgeons. <http://sts.org>)]. JACVSD has developed a software for web-based data collection that enables the data manager at participating hospitals to electronically submit the data to the central office. Although participation in JACVSD is voluntary, data completeness is high, and the accuracy of submitted

[†]Presented at the 27th Annual Meeting of the European Association for Cardio-Thoracic Surgery, Vienna, Austria, 5–9 October 2013.

data is maintained by regular data auditing in which monthly visits are made to participating hospitals to check the reported data against clinical records. Data validity is further confirmed by independent comparison of the cardiac surgery volume at specific hospitals entered in JACVSD with that reported in the annual survey of the Japanese Association for Thoracic Surgery.

Comparison of tricuspid valve replacement with tricuspid valve plasty cases

We examined all patients undergoing tricuspid valve repair after primary cardiac surgery between 1 January 2006 and 31 December 2011. In particular, we compared TVR with TVP cases. JACVSD records obtained without informed patient consent were excluded. Approximately 20% of patients were asymptomatic; however, they had some evidence of deterioration of end-organ function such as that of liver or kidney. Records with missing age (or age out of range), missing sex or missing 30-day status were also excluded.

Hospital death was defined as follows: death from any cause within 30 days after surgery if the patient was discharged from hospital or death at any time if the patient was not discharged. Using the definition from a previous study, major morbidity was defined as any of the following five postoperative in-hospital complications: stroke, reoperation for any reason, mechanical ventilation beyond 24 h after surgery, renal failure or deep sternal wound infection [9, 10].

Statistical analysis

Continuous variables were expressed as mean \pm standard deviation. Categorical variables were compared using the χ^2 test or Fisher's exact test. Continuous variables were compared using Student's *t*-test. In case of non-normal distribution, the non-parametric Wilcoxon test was used. Logistic regression analysis was used to identify independent predictors of clinical outcomes. Predictors associated with a *P* value of <0.2 on univariate analysis were entered into multivariate analysis using stepwise selection. Results were expressed using hazard ratios. Preoperative patient risk factors in the JACVSD risk models were entered as independent variables. All *P* values were two sided, and $P < 0.05$ was considered statistically significant.

RESULTS

There were 167 722 surgical cases from 516 participating institutes throughout Japan registered with JACVSD. After applying the exclusion criteria, the available population for analysis was 1771 cases who underwent tricuspid insufficiency repair following primary cardiac surgery. These included 193 cases of TVR and 1578 cases of TVP.

Baseline characteristics

Comparisons of baseline characteristics between the TVR and TVP groups are presented in Table 1. There were 684 male and 1087 female patients, with an average age of 66.5 ± 10.9 years. Patients in the TVR group were significantly younger than those in the TVP

group ($P = 0.002$). Furthermore, the patients undergoing TVR had a higher prevalence of hypertension and hyperlipidaemia. Among all the patients, 738 (41.7%) were New York Heart Association (NYHA) Class 3 or 4; the TVR group also had a higher incidence of NYHA Class 3 or 4 ($P < 0.001$) and preoperative congestive heart failure within 2 weeks of surgery ($P < 0.001$).

Of the total number of patients, 229 (12.9%) had cerebrovascular disease (CVD), and the prevalence of CVD in the TVP group was higher than that in the TVR group ($P = 0.013$). The prevalence rate of renal failure and infective endocarditis was 171 (9.7%) and 143 (8.1%) cases, respectively, and there was no difference between the groups. Urgent and emergency surgery was required in 61 (3.4%) and 21 patients (1.2%), respectively, and the rates were similar in both groups. The 30-day mortality and hospital mortality calculated by the Japan SCORE were 7.4 ± 9.1 and $10.3 \pm 11.5\%$, respectively, and they were similar between the two groups.

Cardiac status and concomitant procedure

Comparison of cardiac status and concomitant procedures between the TVP and TVR groups are presented in Tables 2 and 3. The TVP group patients had a higher prevalence of aortic valve stenosis ($P = 0.008$), mitral valve stenosis and concomitant aortic valve replacement ($P < 0.001$), mitral valve replacement ($P < 0.001$) and multiple valve operations performed ($P < 0.001$). More than half of the patients in the TVR group underwent single valve operations. The patients in the TVR group also had a higher incidence of TI Grade 3 or 4 ($P < 0.001$) and tricuspid stenosis ($P < 0.001$).

Surgical results

Comparison of surgical results is presented in Table 4. Aortic clamp time was significantly longer in the TVP group (20 min). The overall intubation time was 58 ± 237 h; in the TVR group, it was 115 ± 396 h, which was significantly longer than that in the TVP group ($P < 0.001$). Intensive care unit stay was also significantly longer in the TVR group ($P < 0.001$). Actual mortality was lower than logistic mortality, except for hospital mortality in the TVR group.

Morbidity rates are shown in Table 5. More than 14% of all patients were ventilated for longer than 24 h, and this figure approached 20% in the TVR group. The total number of renal failure and hemodialysis cases was 181 (10.2%) and 100 (5.6%), respectively, with more cases in the TVR group ($P = 0.01$) than in the TVP group ($P = 0.044$). Heart block occurred in 7.8% of the TVR group patients. Gastrointestinal bleeding and multiorgan failure were also significantly higher in the TVR group, at *P* values of 0.008 and 0.001, respectively.

Risk factor analysis

Risk factors for operative death are displayed in Table 6. The following were determined to be risk factors for operative death: age, NYHA Class 4, renal dysfunction, active infective endocarditis, shock, inotropic agent use, aortic stenosis, left ventricular dysfunction and TVR. Preoperative status, including the use of inotropes and shock, also had a high hazard ratio. The hazard ratio for TVR was 3.188.

Table 1: Baseline characteristics

| | Total (n = 1771) | TVR (n = 193) | TV repair (n = 1578) | P value |
|---|------------------|---------------|----------------------|---------|
| Age (years) | 66.5 ± 10.9 | 63.4 ± 13.3 | 66.6 ± 10.5 | 0.002 |
| Body surface area (m ²) | 1.49 ± 0.17 | 1.49 ± 0.17 | 1.49 ± 0.19 | 0.617 |
| Body mass index | 20.9 ± 3.05 | 21.0 ± 3.5 | 20.9 ± 3.0 | 0.445 |
| Male:female | 684:1087 | 71:122 | 613:965 | 0.579 |
| Smoking | 417 (23.5%) | 37 (19.2%) | 380 (24.1%) | 0.129 |
| Diabetes mellitus | 281 (15.9%) | 26 (13.5%) | 255 (16.2%) | 0.335 |
| Diabetes mellitus therapy | 207 (11.7%) | 22 (11.4%) | 185 (11.7%) | 0.895 |
| Hyperlipidaemia | 371 (17.6%) | 18 (9.3%) | 293 (18.6%) | *0.001 |
| Hypertension | 625 (35.3%) | 50 (25.9%) | 575 (36.4%) | *0.004 |
| NYHA 3 or 4 | 738 (41.7%) | 107 (55.4%) | 631 (40.0%) | *<0.001 |
| Canadian Cardiovascular Society 3 or 4 | 77 (4.3%) | 14 (7.3%) | 63 (4.0%) | *0.036 |
| Urgent | 61 (3.4%) | 7 (3.6%) | 54 (3.4%) | 0.883 |
| Emergent | 21 (1.2%) | 2 (1.0%) | 19 (1.2%) | 0.839 |
| Renal failure | 171 (9.7%) | 21 (10.9%) | 150 (9.5%) | 0.541 |
| Hemodialysis | 41 (2.3%) | 3 (1.6%) | 38 (2.4%) | 0.457 |
| Creatinin (mg/dl) | 1.18 ± 5.2 | 1.06 ± 0.62 | 1.20 ± 5.5 | 0.497 |
| Cerebrovascular disorder | 229 (12.9%) | 14 (7.3%) | 215 (13.6%) | *0.013 |
| Recent cerebrovascular disorder | 12 (0.7%) | 2 (1.0%) | 10 (0.6%) | 0.52 |
| Infectious endocarditis | 143 (8.1%) | 14 (7.3%) | 129 (8.2%) | 0.658 |
| Active infectious endocarditis | 76 (4.3%) | 5 (2.3%) | 71 (4.5%) | 0.217 |
| Moderate-to-severe respiratory disorder | 102 (5.8%) | 14 (7.3%) | 88 (5.6%) | 0.345 |
| Extracardiovascular disease | 99 (5.6%) | 11 (5.7%) | 88 (5.6%) | 0.944 |
| Peripheral artery disease | 68 (3.8%) | 7 (3.6%) | 61 (3.9%) | 0.871 |
| Thoracic vascular disease | 48 (2.7%) | 6 (3.1%) | 42 (2.7%) | 0.718 |
| Neurological disorder | 30 (1.7%) | 2 (1.0%) | 28 (1.8%) | 0.453 |
| Myocardial infarction | 50 (2.8%) | 5 (2.6%) | 45 (2.9%) | 0.836 |
| Angina pectoris | 71 (4.0%) | 5 (2.6%) | 66 (4.2%) | 0.287 |
| Unstable angina pectoris | 11 (0.6%) | 1 (0.5%) | 10 (0.6%) | 0.847 |
| Congestive heart disease | 795 (44.9%) | 124 (64.2%) | 671 (42.5%) | *<0.001 |
| Shock | 34 (1.9%) | 4 (2.1%) | 30 (1.9%) | 0.87 |
| Atrial fibrillation | 1053 (59.5%) | 106 (54.9%) | 947 (60.0%) | 0.174 |
| Inotropic agents | 30 (1.7%) | 5 (2.6%) | 25 (1.6%) | 0.306 |
| Percutaneous cardiac intervention | 64 (3.6%) | 6 (3.8%) | 58 (3.7%) | 0.69 |
| Logistic 30-day mortality | 7.4 ± 9.1% | 6.7 ± 9.2% | 7.5 ± 9.1% | 0.257 |
| Logistic operative mortality | 10.3 ± 11.5% | 10.8 ± 11.9% | 10.2 ± 11.4% | 0.532 |
| Logistic 30-day mortality and morbidity | 32.7 ± 14.9% | 36.7 ± 15.6% | 32.2 ± 14.7% | *<0.001 |

TV: tricuspid valve; TVR: tricuspid valve replacement.

*Means significant.

Table 2: Cardiac status

| | Total (n = 1771) | TVR (n = 193) | TV repair (n = 1578) | P-value |
|---------------------------------------|------------------|---------------|----------------------|---------|
| Tricuspid stenosis | 15 (0.8%) | 12 (6.2%) | 15 (0.2%) | *<0.001 |
| Tricuspid valve insufficiency 3 or 4 | 1072 (60.5%) | 149 (77.2%) | 923 (58.5%) | *<0.001 |
| Aortic stenosis | 372 (21%) | 25 (13.0%) | 347 (21.0%) | *0.004 |
| Mitral stenosis | 719 (40.6%) | 26 (13.5%) | 693 (43.9%) | *<0.001 |
| Pulmonary stenosis | 4 (0.2%) | 1 (0.5%) | 3 (0.2%) | 0.365 |
| AV insufficiency 3 or 4 | 141 (8.0%) | 6 (3.1%) | 135 (8.6%) | *0.008 |
| MV insufficiency 3 or 4 | 744 (42%) | 45 (23.3%) | 699 (44.3%) | *<0.001 |
| Triple vessel disease | 38 (2.1%) | 1 (0.5%) | 23 (4.8%) | *0.098 |
| Left main trunk | 31 (1.8%) | 1 (0.5%) | 30 (2.2%) | 0.167 |
| Left ventricle function medium or bad | 818 (46.2%) | 110 (57.0%) | 708 (44.9%) | *0.008 |

AV: aortic valve; MV: mitral valve; TV: tricuspid valve; TVR: tricuspid valve replacement.

*Means significant.

DISCUSSION

Tricuspid valve regurgitation is harmful to long-term survival and can lead to biventricular heart failure. Tricuspid regurgitation,

which is at least moderate, has been associated with increased mortality, regardless of the pulmonary artery systolic pressure of left ventricular ejection fraction [1]. Indeed, guidelines indicate the need for more aggressive treatment of tricuspid regurgitation [11].

Table 3: Concomitant procedures

| | Total (n = 1771) | TVR (n = 193) | TV repair (n = 1578) | P-value |
|---------------------------------|------------------|---------------|----------------------|---------|
| Aortic valve plasty | 19 (1.1%) | 1 (0.5%) | 18 (1.1%) | 0.428 |
| Aortic valve replacement | 467 (26.4%) | 24 (12.4%) | 443 (28.1%) | *<0.001 |
| Mitral valve plasty | 182 (10.2%) | 11 (5.7%) | 170 (10.8%) | *0.028 |
| Mitral valve replacement | 1268 (71.6%) | 67 (34.3%) | 1201 (76.1%) | *<0.001 |
| Single valve operation | 158 (8.9%) | 99 (51.3%) | 59 (3.7%) | *<0.001 |
| Multivalve operation | 1613 (91.1%) | 94 (48.7%) | 1519 (96.3%) | *<0.001 |
| Triple valve operation | 333 (18.8%) | 11 (5.7%) | 322 (20.4%) | *<0.001 |
| Coronary artery bypass grafting | 96 (5.4%) | 4 (2.1%) | 92 (5.8%) | *0.03 |

TV: tricuspid valve; TVR: tricuspid valve replacement.

*Means significant.

Table 4: Surgical outcomes

| | Total (n = 1771) | TVR (n = 193) | TV repair (n = 1578) | P-value |
|---------------------------------------|------------------|---------------|----------------------|---------|
| Operation time (min) | 432 ± 145 | 457 ± 176 | 429 ± 140 | *0.031 |
| Extracorporeal circulation time (min) | 204 ± 80.2 | 201 ± 100 | 204 ± 77 | 0.586 |
| Clamp time (min) | 133 ± 54 | 110 ± 64 | 135 ± 53 | *<0.001 |
| Intubation time (h) | 58 ± 237 | 115 ± 396 | 51 ± 208 | *<0.001 |
| ICU stay longer than 8 days | 260 (14.7%) | 48 (24.9%) | 212 (13.4%) | *<0.001 |
| 30-day mortality (%) | 69 (3.9%) | 13 (6.7%) | 56 (3.6%) | *0.031 |
| Hospital mortality (%) | 120 (6.8%) | 28 (14.5%) | 92 (5.8%) | *<0.001 |
| 30-day mortality and morbidity | 405 (22.9%) | 52 (26.9%) | 353 (22.9%) | 0.153 |

TV: tricuspid valve; TVR: tricuspid valve replacement; ICU: intensive care unit.

*Means significant.

Table 5: Morbidities

| | Total (n = 1771) | TVR (n = 193) | TV repair (n = 1578) | P-value |
|-----------------------------------|------------------|---------------|----------------------|---------|
| Reoperation for bleeding | 137 (7.7%) | 15 (7.8%) | 122 (7.7%) | 0.984 |
| Stroke | 39 (2.2%) | 2 (1.0%) | 37 (2.3%) | 0.242 |
| Prolonged ventilation (over 72 h) | 257 (14.5%) | 38 (19.7%) | 219 (13.9%) | *0.031 |
| Pneumonia | 115 (6.5%) | 25 (13.0%) | 90 (5.7%) | *<0.001 |
| Renal failure | 181 (10.2%) | 30 (15.5%) | 151 (9.6%) | *0.01 |
| Dialysis required | 100 (5.6%) | 17 (8.8%) | 83 (5.3%) | *0.044 |
| Heart block | 73 (4.1%) | 15 (7.8%) | 58 (3.7%) | *0.007 |
| Gastrointestinal bleeding | 55 (3.1%) | 12 (6.2%) | 43 (2.7%) | *0.008 |
| Multiorgan failure | 64 (3.6%) | 15 (7.8%) | 49 (3.1%) | *0.001 |

Prolonged ventilation: ventilation for more than 24 h; Renal failure: postoperative creatinine level twice the preoperative level; TV: tricuspid valve; TVR: tricuspid valve replacement.

*Means significant.

For recurrent cases of isolated tricuspid regurgitation, reoperation is associated with high mortality rates and is rarely recommended [3–5, 12–14]. In this study, many of the patients requiring tricuspid valve repair following cardiac surgery had severe preoperative statuses, with prior congestive heart failure, poor cardiac function, NYHA Class 3 or 4 and CVD. The patients in the TVR group had a higher prevalence of congestive heart failure, NYHA Class 3 or 4 and poor left ventricular function than those in the TVP group.

The TVP group patients had a higher prevalence of comorbid valve disease than the TVR group patients, requiring more concomitant valve procedures rather than a relatively simple, isolated tricuspid valve repair. The patients in the TVR group had higher grades of TI and stenosis requiring isolated TVR operations. Despite the complex multivalve procedures in the TVP group, extracorporeal circulation time was similar between the two groups and operation time was significantly longer in the TVR group. This

Table 6: Risk factors for operative death

| Variables | Univariate <i>P</i> -value | Multivariate <i>P</i> -value | HR | 95% CI |
|--------------------------------|----------------------------|------------------------------|-------|--------------|
| Age | <0.001 | 0.001 | 1.255 | 1.091–1.443 |
| NYHA 4 | <0.001 | <0.001 | 2.739 | 1.569–4.782 |
| Renal dysfunction | <0.001 | 0.001 | 2.575 | 1.554–4.268 |
| Active infectious endocarditis | <0.001 | 0.014 | 2.494 | 1.204–5.164 |
| Shock | <0.001 | 0.002 | 4.189 | 1.727–10.163 |
| Inotropic agents | <0.001 | 0.007 | 3.519 | 1.403–8.824 |
| Aortic stenosis | 0.38 | 0.017 | 1.8 | 1.109–2.924 |
| Left ventricle dysfunction | <0.001 | 0.001 | 2.031 | 1.332–3.097 |
| Tricuspid valve replacement | <0.001 | <0.001 | 3.188 | 1.93–5.266 |

HR: heart rate; 95% CI: 95% confident interval; NYHA: New York Heart Association.

suggests that TVR was performed after failed repair due to severe tricuspid regurgitation and stenosis, resulting in prolonged extracorporeal circulation and operative time. The poorer preoperative status of patients in the TVR group resulted in significantly worse surgical results despite similar surgical results in both groups.

TVR is the last resort for nonrepairable tricuspid pathology. The hospital mortality of TVR is unsurprisingly higher than that of TVP [1, 3, 15, 16]. There are few articles focusing on tricuspid valve reoperation or repair. Park *et al.* [3] and Jeong *et al.* [5] included small samples and reported hospital mortality rates at 0 and 2%, respectively. In an earlier nationwide study that included primary operation, Shabocky *et al.* reported an overall in-hospital mortality rate of 10.6%, with 13.6% in the TVR group and 9.5% in the TVP group [13]. We found an overall mortality rate of 6.8%, with the TVR and TVP groups at 14.5 and 5.8%, respectively. Therefore, our hospital mortality for reoperation was lower.

Various risk factors have been identified previously. Jeong *et al.* [5] reported age and low ejection fraction as risk factors for tricuspid reoperation. Jeganathan *et al.* [12] reported age, male gender, postoperative low cardiac output syndrome and stroke as risk factors for early death with neither pathology nor surgery type influencing early mortality. However, in this study, multivariate analysis revealed that, in addition to the preoperative status (i.e. age, NYHA class, renal function, infective endocarditis, shock, neck vessel stenosis and active infective endocarditis), TVR itself was a major risk factor for operative death, with a hazard ratio of 3.188. To minimize TI after cardiac surgery, it is important to improve a patient's preoperative status and avoid TVR where possible.

According to the ESC/EACTS guideline [17], isolated operation on the tricuspid valve should be considered for persistent or recurrent severe TR after left-sided valve surgery either for symptomatic or asymptomatic patients having progressive RV dilatation or dysfunction. Valve repair is preferable to valve replacement and surgery should be carried out early enough to avoid irreversible RV dysfunction and better management.

Limitations

Although this study is a relatively large-scale, multicentre study, it is retrospective in design. For patients with tricuspid valve disease, liver dysfunction resulting from right-sided heart failure is an important issue; however, data regarding liver function have only

recently been included in JACVSD and have not been obtained in this study. There is a potential selection bias inherent to a database dataset. 'Because of the large number difference between the two groups, good matched pairs or propensity score matching analysis was not possible'.

Furthermore, information on the previous operation was lacking because the categorizations in the database were changed during the study period. The late outcome and quality-of-life data were also not available in the database.

CONCLUSION

In conclusion, we described reoperation for tricuspid valve repair following cardiac surgery. Many of the patients had complex comorbidities and poor cardiac function. Therefore, the operative risk was high, and the results were not entirely satisfactory. However, we were able to determine that TVR itself carries a significant risk of operative mortality. Improvement of a patient's preoperative status and choice of TVP over TVR are important factors that can improve the outcomes of reoperation for tricuspid valve repair following cardiac surgery.

Conflict of interest: none declared.

REFERENCES

- [1] Nath J, Foster E, Heidenreich PA. Impact of tricuspid regurgitation on long-term survival. *J Am Coll Cardiol* 2004;43:405–9.
- [2] Izumi C, Iga KJ, Konishi T. Progression of isolated tricuspid regurgitation late after mitral valve surgery for rheumatic mitral valve disease. *Circ J* 2011;75:2902–7.
- [3] Park CK, Park PW, Sung K, Lee YT, Kim WS, Jun TG. Early and midterm outcomes for tricuspid valve surgery after left-sided valve surgery. *Ann Thorac Surg* 2009;88:1216–23.
- [4] Xiao XJ, Huang HL, Zang JF, Wu RB, He JG, Lu C *et al.* Surgical treatment of late tricuspid regurgitation after left cardiac valve replacement. *Heart Lung Circ* 2004;13:65–9.
- [5] Jeong DS, Park PW, Mwambu TP, Sung K, Kim WS, Lee YT *et al.* Tricuspid reoperation after left-sided rheumatic valve operations. *Ann Thorac Surg* 2013;95:2007–14.
- [6] Motomura N, Miyata H, Tsukihara H, Okada M, Takamoto S. Japan Cardiovascular Surgery Database Organization. First report on 30-day and operative mortality in risk model of isolated coronary artery bypass grafting in Japan. *Ann Thorac Surg* 2008;86:1866–72.

- [7] Motomura N, Miyata H, Tsukihara H, Takamoto S. Risk model of valve surgery in Japan using the Japan Adult Cardiovascular Surgery Database. Japan Cardiovascular Surgery Database Organization. *J Heart Valve Dis* 2010;19:684-91.
- [8] Motomura N, Miyata H, Tsukihara H, Takamoto S. Japan Cardiovascular Surgery Database Organization. Risk model of thoracic aortic surgery in 4707 cases from a nationwide single-race population through a web-based data entry system: the first report of 30-day and 30-day operative outcome risk models for thoracic aortic surgery. *Circulation* 2008;118(14 Suppl):S153-9.
- [9] Shroyer AL, Edwards FH, Grover FL. Updates to the data quality review program: the Society of Thoracic Surgeons Adult Cardiac National Database. *Ann Thorac Surg* 1998;65:1494-7.
- [10] Grover FL, Shroyer AL, Edwards FH, Pae WE Jr, Ferguson TB Jr, Gay WA Jr *et al.* Data quality review program: the Society of Thoracic Surgeons Adult Cardiac National Database. *Ann Thorac Surg* 1996;62:1229-31.
- [11] Bonow RO, Caravello BA, Kanu C, de Leon AC JR, Faxon DP, Freed MD *et al.* ACC/AHA 2006 guidelines for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (writing committee to revise the 1998 Guidelines for the Management of Patients with Valvular Heart Disease): developed in collaboration with the Society of Cardiovascular Anesthesiologists: endorsed by the Society for Cardiovascular Angiography and Interventions and the Society of Thoracic Surgeons. *Circulation* 2006;114:e84-231.
- [12] Jaganathan R, Armstrong S, Al-Alao B, David T. The risk and outcomes of reoperative tricuspid valve surgery. *Ann Thorac Surg* 2013;95:119-25.
- [13] Rogers JH, Bolling SF. The tricuspid valve: current perspective and evolving management of tricuspid regurgitation. *Circulation* 2009;119:2718-25.
- [14] Pfannmuller B, Moz M, Misfeld M, Borger MA, Funkat AK, Garbade J *et al.* Isolated tricuspid valve surgery in patients with previous cardiac surgery. *J Thorac Cardiovasc Surg* 2013;146:841-7.
- [15] Guenther T, Christian N, Mazzitelli D, Busch R, Tassani-Prell P, Lange R. Tricuspid valve surgery: a thirty-year assessment of early and late outcome. *Eur J Cardiothorac Surg* 2008;34:402-9.
- [16] Vassileva CM, Shabosky J, Boley T, Markwell S, Hazelrigg S. Tricuspid valve surgery: the past 10 years from the Nationwide Inpatient Sample (NIS) database. *Thorac Cardiovasc Surg* 2012;143:1043-9.
- [17] The Joint Task Force on the Management of Valvular Heart Disease of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). *Eur J Cardiothorac Surg* 2012;42:S1-44.

APPENDIX. CONFERENCE DISCUSSION

Dr M. Antunes (Coimbra, Portugal): The Tokyo group reviewed the experience of tricuspid reoperation for severe tricuspid regurgitation from the national database. These were not necessarily reoperations on the tricuspid valve but just valve reoperations, the majority of the patients having had only left side valve surgery before. Two subgroups were analysed, patients who required tricuspid valve replacement (fortunately a minority from the results we saw), and those who were treated by valvuloplasty, which is not specified, and I suppose that that means annuloplasty, whether with a ring or with a suture.

Patients who had TVR were much sicker and had far more risk factors, hence, not surprisingly, they had much worse outcome. This is not the result of the type of procedure, and I don't think that the conclusion is correct. You needed to do further statistical analysis to see whether the type of operation itself really was a risk factor. I have doubts about that, except, of course, for AV block, but that requires just careful attention to the technique.

So this is a problem of the patients, not a problem of the type of operation, and for that reason I totally support your conclusion that these patients need to be improved before surgery and, in my experience, that can be done in the vast majority of cases with a significant improvement in the results.

So my question here, and again, it didn't become clear from the abstract or from your presentation, is what triggered reoperation for tricuspid regurgitation, the degree of regurgitation or the symptoms of the patients? And that's important, because not all the patients with severe tricuspid regurgitation get severely symptomatic, and if they are allowed to go too long, the reoperation becomes far more difficult.

And, with regard to all the previous presentations, I am not entirely convinced that the so-called remodelling of the right ventricle will happen necessarily and that it cannot be altered or greatly modified by persistence of intense

anti-failure therapy, which means diuretics and vasodilators. We operate on these patients' left valves, they become totally asymptomatic and medical therapy is usually discontinued. In our practice, we keep these patients on vasodilators and diuretics, irrespective of the absence or presence of symptoms, and we do not have a high prevalence of patients requiring reoperation for tricuspid regurgitation.

My question is, what makes Japanese surgeons decide to go for a tricuspid valve procedure as a reoperation? Was it symptoms or was it the presence of tricuspid regurgitation, because that makes a difference?

Dr S. Saito (Tokyo, Japan): I am a co-author and will answer. The answer to the question is, basically it's the symptoms, rather than the presence of regurgitation. As you have pointed out, reoperative tricuspid surgery for symptomatic patients can be eventually too late. We Japanese surgeons and cardiologists frequently follow-up the patient who had left side surgery, and sometimes a very small amount of tricuspid regurgitation is found during the follow-up echocardiogram. The patients are looked at, together with liver enzyme elevation or symptoms. Basically, when the patient's symptoms become evident, such as oedema or right-sided failure, and are combined with a total bilirubin and liver enzyme elevation, that would be the perfect timing for the reoperation. Nevertheless, the cardiologists are following up the patients for too long, and when we are putting the patient on the operating table, sometimes it is quite difficult to repair. Would that be the answer to your question?

Dr Antunes: More or less. I understand that there are some language problems, but I think I left the message I wanted to give.

eComment. Right ventricular dysfunction in functional tricuspid regurgitation: a word of caution

Author: Ovidio A. Garcia-Villarreal

Department of Cardiac Surgery, Hospital of Cardiology, UMAE 34, IMSS, Monterrey, Mexico

doi: 10.1093/icvts/ivu149

© The Author 2014. Published by Oxford University Press on behalf of the European Association for Cardio-Thoracic Surgery. All rights reserved.

I have read the article by Umehara *et al.* [1] with great interest. The results shown in this paper are not unexpected. I think the decision of whether or not to operate on these patients depends on the state of right ventricular (RV) function. In severe RV dysfunction, functional tricuspid regurgitation (TR) provides the RV with an additional "escape". The choice facing the surgeon is clear. The greater the RV dysfunction, the greater the TR. This emphasis is fully understandable and focused on what occurs beyond the procedure. Mild or moderate functional TR left uncorrected at the time of left-sided valvular surgery can become severe in approximately 34% of cases, with a poor outcome and reduced survival [2]. Quality of life and survival are directly related to residual RV function rather than the type of procedure on the tricuspid valve. The presence of severe pulmonary hypertension and/or significant RV dysfunction can be a relative contraindication to reoperation [3]. Therefore, the risks and benefits of tricuspid valve reoperation should be carefully considered when severe RV systolic dysfunction and/or irreversible pulmonary hypertension are present, due to the possibility of RV failure following the procedure. I strongly recommend the assessment of RV systolic function by echocardiography (tricuspid annular plane systolic excursion >16 mm, tricuspid valve annular velocity >10 cm/s, and RV end-systolic area <20 cm²) as a very important tool in the decision-making process. These observations address the option that these patients might be considered as inoperable [4].

Conflict of interest: none declared.

References

- [1] Umehara N, Miyata H, Motomura N, Saito S, Yamazaki K. Surgical results of reoperative tricuspid surgery: analysis from the Japan Cardiovascular Surgery Database. *Interact CardioVasc Thorac Surg* 2014;19:82-87.
- [2] Dreyfus GD, Corbi PJ, Chan KM, Bahrami T. Secondary tricuspid regurgitation or dilatation: Which should be the criteria for surgical repair? *Ann Thorac Surg* 2005;79:127-32.
- [3] Fukuda S, Gillinov AM, McCarthy PM, Stewart WJ, Song JM, Kihara T *et al.* Determinants of recurrent or residual functional tricuspid regurgitation after tricuspid annuloplasty. *Circulation* 2006;114(Suppl 1):I582-7.
- [4] Garcia-Villarreal OA, Cepeda-Ayala GA. Beyond the tricuspid annuloplasty techniques. *Interact CardioVasc Thorac Surg* 2013;17:738.

Surgical risk model for acute diffuse peritonitis based on a Japanese nationwide database: an initial report on the surgical and 30-day mortality

Tohru Nakagoe · Hiroaki Miyata · Mitsukazu Gotoh · Takayuki Anazawa · Hideo Baba · Wataru Kimura · Naohiro Tomita · Mitsuo Shimada · Yuko Kitagawa · Kenichi Sugihara · Masaki Mori

Received: 4 March 2014 / Accepted: 12 August 2014
© Springer Japan 2014

Abstract

Purpose Acute diffuse peritonitis (ADP) is an important surgical complication associated with high morbidity and mortality; however, the risk factors associated with a poor outcome have remained controversial. This study aimed in collecting integrated data using a web-based national database system to build a risk model for mortality after surgery for ADP.

Methods We included cases registered in the National Clinical Database in Japan. After data cleanup, 8,482 surgical cases of ADP from 1,285 hospitals treated between January 1 and December 31, 2011 were analyzed.

Results The raw 30-day and surgical mortality rates were 9.0 and 14.1 %, respectively. The odds ratios (>2.0) for 30-day mortality were as follows: American Society of Anesthesiologists (ASA) class 3, 2.69; ASA class 4, 4.28; ASA class 5, 8.65; previous percutaneous coronary intervention (PCI), 2.05; previous surgery for peripheral vascular disease (PVD), 2.45 and disseminated cancer, 2.16. The odds ratios (>2.0) for surgical mortality were as follows:

ASA class 3, 2.27; ASA class 4, 4.67; ASA class 5, 6.54, and disseminated cancer, 2.09. The C-indices of 30-day and surgical mortality were 0.851 and 0.852, respectively.

Conclusion This is the first report of risk stratification after surgery for ADP using a nationwide surgical database. This system could be useful to predict the outcome of surgery for ADP and for evaluations and benchmark performance studies.

Keywords Acute diffuse peritonitis · Risk factor · Mortality · Risk model

Introduction

Acute diffuse peritonitis (ADP) is an important surgical complication associated with a high incidence of morbidity and mortality [1–4], and is defined as the uncontained rapid spread of an intra-abdominal infection beyond the organ of origin to multiple (2–4) quadrants of the intra-abdominal cavity, regardless of the underlying disease processes, such as a ruptured appendix, ischemic colitis, gastrointestinal (GI) tract perforation, etc. [2–5]. Emergency surgery is defined as a surgery performed on a patient immediately after the diagnosis [6]. Although a definite preoperative diagnosis of a detailed etiology is difficult even using the recently developed imaging modalities [7, 8], the surgical management of ADP involves immediate evacuation of all purulent collections and source control [1–3].

Although the mortality rate from intra-abdominal infections was close to 90 % in the early 1900s, prior to the introduction of the basic principles of surgery, in the modern era, the reduction in mortality to below 20 % has resulted due to the better understanding of the role of damage control, prevention of intra-abdominal compartment

T. Nakagoe · H. Miyata · M. Gotoh · H. Baba · W. Kimura · N. Tomita · M. Shimada · Y. Kitagawa
The Japanese Society of Gastroenterological Surgery, Database Committee, Tokyo, Japan

H. Miyata · M. Gotoh
National Clinical Database (NCD), Tokyo, Japan

M. Gotoh (✉)
Department of Regenerative Surgery, Fukushima Medical University, 1 Hikarigaoka, Fukushima 960-1295, Japan
e-mail: mgotoh@fmu.ac.jp

T. Anazawa · K. Sugihara · M. Mori
The Japanese Society of Gastroenterological Surgery, Tokyo, Japan

syndrome, and improved antibiotic alternatives with newer, broad-spectrum medications [1]. However, most modern case series of secondary peritonitis with severe sepsis or septic shock have reported an average mortality rate of ~30 % [3].

Knowledge regarding the predictive factors and arrival at a consensus scoring system for the risk of mortality after surgery for ADP would be useful. Many hospitals and surgeons have tried to clarify these factors and develop scoring systems in their own units [1, 3, 9–13]. Although nationwide data regarding the quality of emergency surgical care using the American College of Surgeons-National Surgical Quality Improvement Program (ACS-NSQIP) have been reported in several studies [14–17], to date, there has been no report of a nationwide study focused on ADP.

The National Clinical Database (NCD) in Japan, which commenced patient registration in January 2011, is a nationwide project linked to the surgical board certification system. Submitting cases to the NCD is a prerequisite for all member institutions of both the Japan Surgical Society and the Japanese Society of Gastroenterological Surgery (JSGS), and only registered cases can be used for board certification. The NCD collaborates with the ACS-NSQIP [12], which shares a similar goal of developing a standardized surgery database for quality improvement. The NCD contains >1,200,000 surgical cases collected from >3,500 hospitals in 2011, and risk models of some of the procedures (total gastrectomy, right hemicolectomy, hepatectomy, pancreaticoduodenectomy, hepatectomy, etc.) have been created using these data [18–21]. In this study, a risk model was developed using 8,482 surgical cases of ADP from 1,285 hospitals throughout Japan. This risk model will hopefully contribute to the future improvement in the quality control of surgery for ADP.

Methods

Data acquisition

The NCD continuously recruits individuals to approve the inputted data from members of various departments in charge of annual cases, as well as data entry officers, through a web-based data management system to assure the traceability of the data. Furthermore, the project managers consecutively and consistently validate the data by inspection of randomly chosen institutions.

In this study, we focused on ADP cases in the GI surgery section of the NCD that were characterized by variables and definitions that were almost identical to those applied in the ACS-NSQIP [14–17, 22]. In the GI surgery section, all of the surgical cases are registered and require detailed input items for the eight procedures representing

the performance of surgery in each specialty (low anterior resection, right hemicolectomy, hepatectomy, total gastrectomy, partial gastrectomy, pancreaticoduodenectomy, esophagectomy, and ADP). All variables, definitions and inclusion criteria regarding the NCD are accessible from the website (<http://www.ncd.or.jp/>) to participate institutions, and are also intended to support an E-learning system in order for participants to input consistent data. The NCD provides answers to all queries regarding data entry (~80,000 inquiries in 2011) and regularly includes the responses to some of the queries as Frequently Asked Questions on the website.

Patient selection

A total of 8,482 patients who underwent surgery for ADP were identified from the NCD in 2011. Most of the patients who underwent surgery for ADP required emergency surgery within 24 h after admission, because the condition of the patients would otherwise have proven fatal or would have caused severe damage to the patients. This is differentiated from localized intra-abdominal abscess, which allows for a time-rich detailed exploration. Surgery for ADP (i.e., surgical debridement and/or drainage) is a procedure representing the performance of a surgery that has been allowed by the national Japanese insurance system. To reduce the bacterial load, the abdominal cavity is lavaged, with particular attention to areas prone to abscess formation (e.g., the paracolic gutters and subphrenic areas). When surgery is performed to address underlying diseases or resection of a perforated viscus with reanastomosis or the creation of a fistula, supplemental procedures, such as resection of the small intestine, colorectal resection and enterostomy, are also recorded. The NCD allows the inclusion of up to eight ICD-10 codes for the preoperative/postoperative diagnosis of each case. Possible causative diseases necessitating surgery in the NCD include peritonitis, intestinal perforation, appendicitis, gastroduodenal ulcer/perforation, intestinal obstruction and vascular insufficiency, etc.

Pre- and perioperative variables

The potential independent variables included the patient demographics, pre-existing comorbidities, preoperative laboratory values, and perioperative data. The demographic variables of age, gender, smoking status, and drinking status were considered. Patients were categorized on the basis of whether they were transferred directly by ambulance or not. General factors, such as the preoperative functional status [independent, partially dependent, and totally dependent with regard to a patient's ability to perform activities of daily living (ADL) 30 days and immediately before surgery] and the body mass index (BMI), were

also considered. The ASA physical status classification was evaluated. We also considered preexisting comorbidities, including the cardiovascular status (congestive heart failure, coronary diseases, hypertension, previous cardiac surgery, and peripheral vascular disease), respiratory status (dyspnea, ventilator dependence, pneumonia, and chronic obstructive pulmonary disease), renal status (acute renal failure and dialysis), hematological status (bleeding disorders and preoperative blood transfusion), oncological status (disseminated cancer, chemotherapy and radiotherapy), preoperative blood transfusion, chronic steroid use, ascites, sepsis, diabetes, open wound, and pregnancy. The laboratory parameters included in the analysis were the white blood cell count, hemoglobin level, hematocrit, platelet count, prothrombin time and activated partial thromboplastin time, as well as the serum levels of albumin, total bilirubin, aspartate amino transferase, alanine aminotransferase, alkaline phosphatase, urea nitrogen, creatinine, sodium, hemoglobin A1c, and C-reactive protein (CRP). The length of the surgery, intraoperative blood loss and relaparotomy within 30 days after surgery for ADP were also considered. A total of 4,192 supplemental procedures for source control were also included.

Endpoints

The outcome measures of this study were the 30-day and surgical mortality rates. The former was defined as death within 30 days of surgery regardless of the patient's geographical location, even if the patient had been discharged from the hospital. The latter was defined as death within the index hospitalization period, regardless of the length of hospital stay (up to 90 days), as well as any patient who died after being discharged, up to 30 days from the date of surgery.

Statistical analysis

Data were randomly assigned into two subsets that were split 80/20, the first for model development, and the second

for validation. The two sets of logistic models (30-day mortality and surgical mortality) were constructed for dataset development using stepwise selection of the predictors with a probability (*P*) value for inclusion of 0.05. A "goodness-of-fit" test was performed to assess how efficiently the model could discriminate between surviving and deceased patients. Model calibration (the degree to which the observed outcomes were similar to the predicted outcomes from the model across patients) was examined by comparing the observed with the predicted average within each of 10 equally sized subgroups arranged in increasing order of patient risk [6, 23].

Results

Outcomes

Among the data for the 8,482 patients stored in the NCD for 2011, the 30-day and postoperative mortality rates for ADP were 9.0 and 14.1 %, respectively. The causative diseases leading to the need for surgery are listed in Table 1. The development dataset (test set) included 6,759 records, and the validation dataset (validation set) included 1,723 records (Table 2). The rates of relaparotomy and readmission within 30 days in all records were 8.1 and 1.7 %, respectively, in these datasets.

Risk profile for the study population

The patient population that underwent surgery for ADP had an average age of 64.7 years (SD 18.6), 59.8 % of whom were males, and 38.7 % of patients were taken to the hospital by ambulance, 93.1 % of whom required emergency surgery. An abbreviated risk profile of the study population is shown in Table 3. The patients with partially/totally dependent and totally dependent evaluations of the ADL within 30 days before surgery comprised 20.7 and 7.7 % of the patients, respectively. Only 0.6 % of the patients had a BMI ≥ 35 kg/m². Of the included patients, 43.2 %

Table 1 The causative disease leading to the need for surgery

| Diagnosis | Number | 30-Day mortality | | Surgical mortality | |
|----------------------------------|--------|------------------|-------------|--------------------|-------------|
| | | Number | Percent (%) | Number | Percent (%) |
| Acute peritonitis | 4,378 | 429 | 9.8 | 652 | 14.9 |
| Appendicitis | 1,183 | 4 | 0.3 | 10 | 0.8 |
| Intestinal perforation | 1,576 | 148 | 12.9 | 222 | 19.3 |
| Gastroduodenal ulcer/perforation | 833 | 63 | 7.3 | 64 | 9.7 |
| Intestinal obstruction | 396 | 50 | 12.6 | 80 | 20.2 |
| Cholecystitis/cholangitis | 218 | 18 | 9.0 | 26 | 13.1 |
| Vascular insufficiency | 121 | 21 | 17.4 | 35 | 28.9 |
| All cases | 8,482 | 762 | 9.0 | 1,195 | 14.1 |

The listed diseases were not mutually exclusive
Causative diseases with fewer than 100 cases were not listed

Table 2 The outcomes of surgery for acute diffuse peritonitis

| Outcomes | Test set (<i>n</i> = 6,759) | | Validation set (<i>n</i> = 1,723) | | Overall incidence (<i>n</i> = 8,482) | |
|-----------------------------|---------------------------------|-------------|---------------------------------------|-------------|--|-------------|
| | Number | Percent (%) | Number | Percent (%) | Number | Percent (%) |
| 30-Day mortality | 604 | 8.9 | 158 | 9.2 | 762 | 9.0 |
| In-hospital mortality | 938 | 13.9 | 241 | 14.0 | 1,179 | 13.9 |
| Surgical mortality | 950 | 14.1 | 245 | 14.2 | 1,195 | 14.1 |
| Relaparotomy within 30 days | 546 | 8.1 | 145 | 8.4 | 691 | 8.1 |
| Readmission within 30 days | 107 | 1.6 | 39 | 2.3 | 146 | 1.7 |

were ASA class 3–5. Regarding preexisting comorbidities, 20.5 % of patients had received preoperative blood transfusions, 22.7 % had ascites, 31.8 % had sepsis, and 13.5 % had diabetes.

The types of supplemental surgical procedures (*n* = 4,192) performed for source control are listed in Table 4. The primary surgical procedures were enterostomy (30.4 %), colorectal resection (19.9 %), closure of a perforated stomach/duodenum (13.0 %), appendectomy (12.4 %), resection of the small intestine (8.2 %), the Hartmann procedure (6.5 %), cholecystectomy/cholecystotomy (3.5 %), closure of a perforated small intestine (3.3 %), and surgery for intestinal obstruction (2.5 %).

Model results

Two different risk models were developed, and the final logistic model with odds ratios and 95 % confidence intervals are presented in Table 5. The scoring system for the mortality risk models according to the logistic regression equation was as follows:

Predicted mortality = $e(\beta_0 + \sum \beta_i X_i) / 1 + e(\beta_0 + \sum \beta_i X_i)$, where β_i is the coefficient of the variable X_i in the logistic regression equation provided in Table 5 for the 30-day mortality and surgical mortality. $X_i = 1$ if a categorical risk factor is present and 0 if it is absent. For the age category, $X_i = 1$ if the patient age is <59 years old; 2 if the patient age is between 60 and 64; 3 if 65 and 69; four if 70 and 74; 5 if 75–79 and the $X_i = 6$ if the age was ≥ 80 years old. Between the two models, there were 16 overlapping variables: the age, ASA class 5, ASA class 4, ASA class 3, disseminated cancer, nontumor-bearing, preoperative transfusion, chronic steroid use, serum albumin <2.0 g/dL, serum total bilirubin ≥ 3.0 mg/dL, serum AST ≥ 35 U/L, serum ALP ≥ 600 U/L, serum urea nitrogen ≥ 20 or 25 mg/dL, serum Na <130 mEq/L and serum CRP ≥ 10.0 mg/dL.

The important variables (odds ratio >2.0) affecting the 30-day mortality were ASA class 3 (OR, 2.69; 95 % CI, 2.05–3.54), ASA class 4 (OR, 4.28; 95 % CI, 3.11–5.87),

ASA class 5 (OR, 8.65; 95 % CI, 6.14–12.18), previous PCI (OR, 2.05; 95 % CI, 1.26–3.31), previous PVD surgery (OR, 2.45; 95 % CI, 1.16–5.17) and disseminated cancer (OR, 2.16; 95 % CI, 1.53–3.05), whereas those affecting the surgical mortality were ASA Class 3 (OR, 2.27; 95 % CI, 1.83–2.82), ASA Class 4 (OR, 4.67; 95 % CI, 3.61–6.05), ASA class 5 (OR, 6.54; 95 % CI, 4.83–8.84) and disseminated cancer (OR, 2.09; 95 % CI, 1.54–2.83).

Model performance

To evaluate the model performance, both a C-index (a measure of model discrimination) with a 95 % CI, which is the area under the receiver operating characteristic curve, and the model calibration across risk groups were evaluated. As a performance parameter of the risk model, the C-indices of the 30-day and surgical mortality were 0.851 (95 % CI, 0.822–0.880) and 0.852 (95 % CI, 0.828–0.875), respectively (Fig. 1). Figure 2 demonstrates the calibration of the models and how well the rates for the predicted events matched those of the observed events among the patient risk subgroups.

Discussion

Systemic sepsis is a life-threatening condition that may occur as a result of intra-abdominal infections of all types [1, 3]. In complicated intra-abdominal infections, the infection spreads beyond the organ of origin and causes either localized or diffuse peritonitis [2, 10]. Complicated intra-abdominal infections represent an important cause of morbidity, and are frequently associated with a poor prognosis [2, 10]. The mortality is reportedly reduced by 50 % following the introduction of the basic concepts of surgery for intra-abdominal infections by: (1) elimination of the septic foci, (2) removal of necrotic tissue and (3) drainage of purulent material. Advances that have provided a better understanding of the pathophysiology, the role of damage control, the prevention of intra-abdominal

Table 3 Key risk profiles and outcomes

| | Records for the entire study population (<i>n</i> = 8,482) | | Outcome groups | | | |
|---|--|---------|---------------------------------------|---------|---|---------|
| | Number | Percent | 30-Day mortality (<i>n</i> = 762) | | Surgical mortality (<i>n</i> = 1,195) | |
| | | | Number | Percent | Number | Percent |
| Characteristics | | | | | | |
| Demographics | | | | | | |
| Age, mean (SD), years | 64.7 (18.6) | | 74.8 (13.7) | | 74.5 (13.2) | |
| Males | 5,072 | 59.8 | 416 | 8.2 | 667 | 13.2 |
| Ambulance transportation | 3,283 | 38.7 | 364 | 11.1 | 511 | 15.6 |
| Preoperative risk assessment | | | | | | |
| General | | | | | | |
| ADL within 30 days before surgery | | | | | | |
| Partially/totally dependent | 1,756 | 20.7 | 342 | 19.5 | 535 | 30.5 |
| Totally dependent | 653 | 7.7 | 149 | 22.8 | 231 | 35.4 |
| ADL immediately before surgery | | | | | | |
| Partially/totally dependent | 2,358 | 27.8 | 427 | 18.1 | 654 | 27.7 |
| Totally dependent | 1,162 | 13.7 | 258 | 22.2 | 375 | 32.3 |
| Body mass index ≥ 35 kg/m ² | 51 | 0.6 | 11 | 20.8 | 14 | 28.3 |
| Weight loss over 10 % | 442 | 5.2 | 77 | 17.4 | 134 | 30.3 |
| ASA class 3, ASA class 4, or ASA class 5 | 3,664 | 43.2 | 641 | 17.5 | 976 | 26.6 |
| Cardiovascular | | | | | | |
| Congestive heart failure | 237 | 2.8 | 71 | 30.0 | 103 | 43.4 |
| Previous myocardial infarction | 51 | 0.6 | 14 | 27.5 | 18 | 35.3 |
| Angina pectoris | 110 | 1.3 | 20 | 18.2 | 26 | 23.6 |
| Hypertension without therapy | 271 | 3.2 | 27 | 10.0 | 45 | 16.7 |
| Previous PCI | 170 | 2 | 37 | 22.0 | 44 | 26.2 |
| Previous cardiac surgery | 119 | 1.4 | 28 | 23.3 | 35 | 29.3 |
| Previous surgery for PVD | 51 | 0.6 | 14 | 28.3 | 24 | 47.2 |
| Pulmonary | | | | | | |
| Dyspnea | 712 | 8.4 | 192 | 27.0 | 267 | 37.4 |
| Ventilator-dependent | 331 | 3.9 | 98 | 29.6 | 147 | 44.3 |
| Pneumonia | 305 | 3.6 | 84 | 27.6 | 125 | 40.9 |
| COPD | 288 | 3.4 | 46 | 15.8 | 71 | 24.6 |
| Renal | | | | | | |
| Acute renal failure | 407 | 4.8 | 127 | 31.1 | 177 | 43.5 |
| Dialysis | 322 | 3.8 | 79 | 24.4 | 118 | 36.7 |
| Oncological | | | | | | |
| Non-tumor-bearing | 7,490 | 88.3 | 618 | 8.3 | 947 | 12.6 |
| Disseminated cancer | 450 | 5.3 | 95 | 21.2 | 161 | 35.8 |
| Chemotherapy | 297 | 3.5 | 49 | 16.6 | 101 | 33.9 |
| Radiotherapy | 51 | 0.6 | 9 | 17.0 | 14 | 27.7 |
| Hematological | | | | | | |
| Bleeding disorder without therapy | 560 | 6.6 | 159 | 28.5 | 214 | 38.2 |
| Preoperative blood transfusion | 1,739 | 20.5 | 351 | 20.2 | 535 | 30.8 |
| Other | | | | | | |
| Previous cerebrovascular disease | 450 | 5.3 | 76 | 17.0 | 119 | 26.4 |
| Chronic steroid use | 365 | 4.3 | 71 | 19.4 | 109 | 29.9 |
| Ascites without therapy | 1,925 | 22.7 | 259 | 13.4 | 412 | 21.4 |
| Sepsis | 2,697 | 31.8 | 453 | 16.8 | 661 | 24.5 |

Table 3 continued

| | Records for the entire study population (n = 8,482) | | Outcome groups | | | |
|---|--|---------|-------------------------------|---------|-----------------------------------|---------|
| | Number | Percent | 30-Day mortality (n = 762) | | Surgical mortality (n = 1,195) | |
| | | | Number | Percent | Number | Percent |
| Diabetes | 1,145 | 13.5 | 152 | 13.3 | 241 | 21.0 |
| Preoperative laboratory value | | | | | | |
| White blood cell count <4,500/ μ L | 1,993 | 23.5 | 253 | 12.7 | 382 | 19.2 |
| White blood cell count <4,000/ μ L | 1,789 | 21.1 | 230 | 12.9 | 345 | 19.3 |
| Hemoglobin <13.5 g/dL in males; <12.5 g/dL in females | 4,419 | 52.1 | 541 | 12.3 | 886 | 20.1 |
| Hemoglobin < 10.0 g/dL | 1,734 | 20.4 | 268 | 15.5 | 442 | 25.5 |
| Hematocrit <30 % | 1,671 | 19.7 | 264 | 15.8 | 440 | 26.3 |
| Platelet count <15,000/ μ L | 1,484 | 17.5 | 297 | 20.0 | 406 | 27.4 |
| Platelet count <12,000/ μ L | 771 | 9.1 | 192 | 24.9 | 260 | 33.7 |
| Platelet count <8,000/ μ L | 288 | 3.4 | 104 | 36.1 | 137 | 47.6 |
| Serum albumin <2.0 g/dL | 619 | 7.3 | 141 | 22.8 | 225 | 36.4 |
| Serum albumin <2.5 g/dL | 1,612 | 19 | 291 | 18.1 | 491 | 30.5 |
| Serum albumin <3.0 g/dL | 2,943 | 34.7 | 450 | 15.3 | 746 | 25.3 |
| Serum total bilirubin \geq 3.0 mg/dL | 365 | 4.3 | 76 | 20.9 | 113 | 31.0 |
| Serum AST \geq 35 U/L | 2,036 | 24 | 331 | 16.2 | 483 | 23.8 |
| Serum ALP \geq 340 U/L | 1,442 | 17 | 199 | 13.8 | 317 | 22.0 |
| Serum ALP \geq 600 U/L | 407 | 4.8 | 76 | 18.8 | 113 | 27.8 |
| Serum urea nitrogen \geq 20 mg/dL | 3,868 | 45.6 | 596 | 15.4 | 898 | 23.2 |
| Serum urea nitrogen \geq 25 mg/dL | 2,748 | 32.4 | 503 | 18.3 | 736 | 26.8 |
| Serum creatinine \geq 1.2 mg/dL | 2,171 | 25.6 | 401 | 18.5 | 591 | 27.2 |
| Serum creatinine \geq 2.0 mg/dL | 984 | 11.6 | 216 | 22.0 | 320 | 32.5 |
| Serum Na <130 mEq/L | 475 | 5.6 | 78 | 16.5 | 135 | 28.3 |
| Serum Na <135 mEq/L | 1,976 | 23.3 | 245 | 12.4 | 398 | 20.1 |
| Serum Na \geq 145 mEq/L | 314 | 3.7 | 71 | 22.5 | 95 | 30.2 |
| Serum CRP \geq 10.0 mg/dL | 3,927 | 46.3 | 369 | 9.4 | 611 | 15.6 |
| Operation | | | | | | |
| Length of operation \geq 6 h | 51 | 0.6 | 12 | 24.0 | 16 | 32.0 |
| Intraoperative blood loss \geq 2,000 mL | 161 | 1.9 | 40 | 24.5 | 62 | 38.2 |
| Relaparotomy within 30 days | 687 | 8.1 | 81 | 11.7 | 163 | 23.7 |

SD standard deviation, ADL activities of daily living, ASA class American Society of Anesthesiologists Physical Status Classification, PCI percutaneous coronary intervention, PVD peripheral vascular disease, COPD chronic obstructive pulmonary disease, AST aspartate amino transferase, ALP alkaline phosphatase, Na sodium, CRP C-reactive protein

compartment syndrome and antibiotic administration have collectively helped to reduce the mortality rate below 20 % [1].

In this study, the 30-day and surgical mortality rates after surgery for all acute types of primary, secondary and tertiary peritonitis [1–3] were 9.0 and 14.1 %, respectively. Recently, published studies reported that the 30-day mortality rate after surgery for ADP was 8–9 % [24, 25], whereas the surgical mortality rate was 12.8–33.3 % (12.8 % [26], 14 % [5], 19 % [24], 22 % [27], 21.8 % [12], 23.1 % [11] and 33.3 % [28]). For reference, the 30-day mortality rate of the patients in the ACS-NSQIP study of

5,083 patients who underwent emergency colorectal operations was 15.4 % [17]. Thus, although the 30-day mortality rate in this study was similar to that in previous studies, the surgical mortality rates in the previous studies from western countries was higher than that in the current study. We believe that our results were satisfactory for a nationwide outcome of surgery for ADP.

Early prognostic evaluation of complicated intra-abdominal infections is important to assess the severity and prognosis of disease [10]. A number of factors influencing the prognosis of patients with complicated intra-abdominal infections, as well as scoring systems to evaluate these

Table 4 Supplemental surgical procedures performed for source control and the outcomes

| Surgical | Surgical procedures | | Outcome groups | | | |
|---|---------------------|---------|------------------|---------|--------------------|---------|
| | | | 30-Day mortality | | Surgical mortality | |
| | Number | Percent | Number | Percent | Number | Percent |
| Gastro-duodenum | | | | | | |
| Closure of perforated stomach and/or duodenum | 545 | 13.0 | 35 | 6.4 | 46 | 8.4 |
| Gastrectomy | 75 | 1.8 | 7 | 9.3 | 8 | 10.7 |
| Postduodenal small intestine | | | | | | |
| Resection of small intestine | 345 | 8.2 | 35 | 10.1 | 67 | 19.4 |
| Closure of perforated intestine | 138 | 3.3 | 10 | 7.2 | 22 | 15.9 |
| Surgery for intestinal obstruction | 106 | 2.5 | 21 | 19.8 | 30 | 28.3 |
| Enterostomy | 1,276 | 30.4 | 185 | 14.5 | 280 | 21.9 |
| Appendix | | | | | | |
| Appendectomy | 519 | 12.4 | 4 | 0.8 | 11 | 2.1 |
| Colon and rectum | | | | | | |
| Right-sided colon resection | 177 | 4.2 | 19 | 10.7 | 32 | 18.1 |
| Left-sided colon resection | 326 | 7.8 | 47 | 14.4 | 68 | 20.9 |
| Anterior resection | 22 | 0.5 | 2 | 9.1 | 2 | 9.1 |
| Hartmann procedure | 273 | 6.5 | 32 | 11.7 | 44 | 16.1 |
| Total colectomy | 19 | 0.5 | 4 | 21.1 | 5 | 26.3 |
| Hepato-biliary-pancreatic | | | | | | |
| Hepatic resection/suturing the liver | 8 | 0.2 | 1 | 12.5 | 2 | 25.0 |
| Cholecystectomy/cholecystostomy | 151 | 3.6 | 12 | 8.1 | 20 | 13.4 |
| Choledocholithotomy/choledochoduodenostomy (-jejunostomy)/choledochostomy | 29 | 0.7 | 7 | 25.0 | 7 | 25.0 |
| Surgery for acute pancreatitis/resection of the pancreas/Drainage of pancreatic duct or cyst, % | 8 | 0.2 | 2 | 22.2 | 4 | 44.4 |
| Others | | | | | | |
| Abdominoperineal resection/total pelvic exenteration | 17 | 0.4 | 4 | 22.2 | 4 | 22.2 |
| Splenectomy | 13 | 0.3 | 3 | 21.4 | 4 | 28.6 |

A total of 4,192 supplemental surgical procedures were included. Surgical procedures performed fewer than eight times were not listed. Some patients underwent more than one surgical procedure

factors, have been reported [3, 10–13, 24]. From our risk model, the important variables identified to affect the 30-day mortality rate were ASA class 3, ASA class 4, ASA class 5, previous percutaneous coronary intervention (PCI), previous surgery for peripheral vascular disease (PVD) and disseminated cancer, whereas those affecting the surgical mortality rate were ASA class 3, ASA class 4, ASA class 5 and disseminated cancer. Although the ASA classification of fitness for surgery was not devised as a risk prediction score, several studies have reported the association between the ASA class and observed postoperative mortality in elderly patients following emergency GI surgery [13, 29]. In univariate and multivariate analyses of the mortality of emergency surgical patients, the ASA class has been consistently shown to be a good predictor of postoperative death, although this is despite its subjective nature and the inter-observer variations in measuring the ASA class [13].

Other significant factors identified by our risk assessment model, including age, ambulance transportation, the ADL, respiratory distress, preoperative pneumonia, bleeding disorders, preoperative blood transfusion and long-term steroid use, were also significant risk factors for the 30-day and/or surgical mortality. Several risk factors (age, dyspnea, previous PCI, disseminated cancer, long-term steroid use, bleeding disorder without therapy and preoperative blood transfusion) have been reported in previous studies [31, 32], although ambulance transportation and the ADL have not been previously reported. The rate of ambulance transport among the elderly is continually increasing along with the rapidly aging population in Japan [33]. In this study, 38.7 % of the 8,482 patients who underwent surgery for ADP were admitted to a hospital by direct ambulance transport. Among the critical components of health care systems, ambulance services play an important

Table 5 The odds ratios with 95 % confidence intervals for the risk models of surgery for acute diffuse peritonitis

| Variables | 30-Day mortality | | | | Surgical mortality | | | |
|--|---------------------|------|------------|---------|---------------------|------|-----------|---------|
| | β coefficient | OR | 95 % CI | P value | β coefficient | OR | 95 % CI | P value |
| Demographics | | | | | | | | |
| Age category ^a | 0.211 | 1.24 | 1.17–1.31 | <0.001 | 0.234 | 1.26 | 1.20–1.33 | <0.001 |
| Ambulance transport | 0.317 | 1.37 | 1.12–1.68 | 0.002 | | | | |
| Respiratory distress | 0.462 | 1.59 | 1.22–2.06 | <0.001 | | | | |
| ADL, totally dependent immediately before surgery | 0.337 | 1.4 | 1.11–1.77 | 0.005 | | | | |
| ADL, totally dependent within 30 days before surgery | | | | | 0.465 | 1.59 | 1.22–2.07 | 0.001 |
| ADL, partially/totally dependent immediately before surgery, | | | | | 0.303 | 1.35 | 1.12–1.64 | 0.002 |
| Preoperative pneumonia | | | | | 0.342 | 1.41 | 1.01–1.97 | 0.045 |
| ASA class 5 | 2.157 | 8.65 | 6.14–12.18 | <0.001 | 1.877 | 6.54 | 4.83–8.84 | <0.001 |
| ASA class 4 | 1.453 | 4.28 | 3.11–5.87 | <0.001 | 1.542 | 4.67 | 3.61–6.05 | <0.001 |
| ASA class 3 | 0.99 | 2.69 | 2.05–3.54 | <0.001 | 0.822 | 2.27 | 1.83–2.82 | <0.001 |
| Preexisting comorbidity | | | | | | | | |
| Previous PCI | 0.715 | 2.05 | 1.26–3.31 | 0.004 | | | | |
| Previous surgery for PVD | 0.897 | 2.45 | 1.16–5.17 | 0.018 | | | | |
| Disseminated cancer | 0.769 | 2.16 | 1.53–3.05 | <0.001 | 0.735 | 2.09 | 1.54–2.83 | <0.001 |
| Non tumor-bearing | −0.436 | 0.65 | 0.48–0.87 | 0.003 | −0.69 | 0.5 | 0.4–0.64 | <0.001 |
| Bleeding disorder without therapy | 0.499 | 1.65 | 1.24–2.19 | 0.001 | 0.484 | 1.62 | 1.31–2.01 | <0.001 |
| Preoperative blood transfusion | 0.472 | 1.6 | 1.13–2.28 | 0.009 | 0.595 | 1.81 | 1.32–2.49 | <0.001 |
| Chronic steroid use | 0.552 | 1.74 | 1.21–2.50 | 0.003 | 0.651 | 1.92 | 1.39–2.65 | <0.001 |
| Weight loss over 10 % | | | | | 0.331 | 1.39 | 1.02–1.90 | 0.036 |
| Preoperative laboratory value | | | | | | | | |
| White blood cell count <4,500/ μ L | | | | | 0.404 | 1.5 | 1.25–1.8 | <0.001 |
| White blood cell count <4,000/ μ L | 0.336 | 1.4 | 1.12–1.75 | 0.003 | | | | |
| Hemoglobin <13.5 g/dL in males; <12.5 g/dL in females | | | | | 0.273 | 1.31 | 1.07–1.62 | 0.01 |
| Hemoglobin <10.0 g/dL | 0.254 | 1.29 | 1.03–1.61 | 0.024 | | | | |
| Hematocrit <30 % | | | | | 0.209 | 1.23 | 1.01–1.51 | 0.044 |
| Platelet count <15,000/ μ L | 0.413 | 1.51 | 1.19–1.92 | 0.001 | | | | |
| Platelet count <12,000/ μ L | | | | | 0.356 | 1.43 | 1.13–1.8 | 0.003 |
| Platelet count <8,000/ μ L | 0.424 | 1.53 | 1.03–2.26 | 0.033 | | | | |
| Serum albumin <2.0 g/dL | 0.51 | 1.67 | 1.25–2.22 | <0.001 | 0.394 | 1.48 | 1.14–1.93 | 0.003 |
| Serum albumin <3.0 g/dL | | | | | 0.316 | 1.37 | 1.13–1.67 | 0.002 |
| Serum total bilirubin \geq 3.0 mg/dL | 0.532 | 1.7 | 1.16–2.49 | 0.006 | 0.676 | 1.97 | 1.40–2.76 | <0.001 |
| Serum AST \geq 35 U/L | 0.3 | 1.35 | 1.09–1.67 | 0.006 | 0.358 | 1.43 | 1.19–1.72 | <0.001 |
| Serum ALP \geq 600 U/L | 0.545 | 1.73 | 1.18–2.51 | 0.005 | 0.474 | 1.61 | 1.15–2.24 | 0.005 |
| Serum urea nitrogen \geq 20 mg/dL | 0.569 | 1.77 | 1.28–2.43 | 0.001 | 0.563 | 1.76 | 1.35–2.29 | <0.001 |
| Serum urea nitrogen \geq 25 mg/dL | 0.343 | 1.41 | 1.06–1.88 | 0.02 | | | | |
| Serum creatinine \geq 2.0 mg/dL | | | | | 0.405 | 1.5 | 1.2–1.89 | <0.001 |
| Serum Na <130 mEq/L | 0.521 | 1.68 | 1.21–2.35 | 0.002 | 0.56 | 1.75 | 1.31–2.33 | <0.001 |
| Serum Na \geq 145 mEq/L | 0.526 | 1.69 | 1.16–2.46 | 0.006 | | | | |
| Serum CRP \geq 10.0 mg/dL | 0.397 | 1.49 | 1.21–1.83 | <0.001 | 0.423 | 1.53 | 1.27–1.83 | <0.001 |
| Intercept (β 0) | −5.449 | | | <0.001 | −4.83 | | | <0.001 |

ADL activities of daily living, ASA class American Society of Anesthesiologists Physical Status Classification, PCI percutaneous coronary intervention, PVD peripheral vascular disease, COPD chronic obstructive pulmonary disease, AST aspartate amino transferase, ALP alkaline phosphatase, Na sodium, CRP C-reactive protein, OR odds ratio, CI confidence interval

^a Age, years, <59, 60–64, 65–69, 70–74, 75–79, \geq 80




Fig. 1 The receiver operating characteristics (ROC) curves for the 30-day mortality (a) and surgical mortality (b) in the validation set

part in the continuum of health care by providing prehospital care and transport in emergency situations [33]. The ADL describes the essential activities that a person needs to perform to be able to live independently. Particularly in the aging individual, the combination of acute and chronic diseases often results in disabilities and limitations in the ADL [34]. Functional limitations are particularly associated with mortality in patients with hip fractures and pulmonary infections, and in acute medical patients [34, 35]. In this risk model, not only the ADL (totally dependent) immediately before surgery, but also the ADL (totally/partially dependent) within 30 days before surgery was a significant risk factor for surgical mortality. These data suggest that assessment of the ADL within 30 days before surgery should be considered for the clinical management of ADP.

From our risk model, 12 laboratory factors (white blood cell count, hemoglobin, hematocrit, platelet count,




Fig. 2 The model calibration for the 30-day (a) and surgical (b) mortality models

and the serum levels of albumin, total bilirubin, aspartate amino transferase, alkaline phosphatase, urea nitrogen, creatinine, sodium and CRP) were significant risk factors for the 30-day and surgical mortality. These laboratory data may reflect the degree of physiological derangement due to the intra-abdominal infection and preexisting critical illness, and have been reported in previous studies.

The C-indices of the models for the 30-day and surgical mortality in this study were 0.851 and 0.852,

respectively. These data indicate that our models were reliable. Although the usefulness of several scoring systems, such as the Acute Physiology and Chronic Health Evaluation (APACHE) score and the Mannheim Peritonitis Index, have been reported [13], they are not specific for Japanese patients who undergo surgery for ADP. The reliability of existing scores or indices for ADP surgery may be improved by including our risk model. The NCD collects data obtained before admission and during the hospitalization period. On the other hand, the APACHE database is a collection of data obtained only after the patient has been admitted to the intensive care unit [14]. Some NCD preoperative data were predictive of the patient outcomes, which may allow for the earlier identification of potential complications.

This study was associated with several potential limitations. First, except for the ASA class, the other scoring systems to potentially predict the mortality after surgery for ADP, such as the APACHE score and Mannheim Peritonitis Index [13], could not be determined from this database. Second, we could not distinguish between the two different types of intra-abdominal infections (community- and healthcare-acquired), from this database. Third, the risk of mortality differed between ADP due to upper gastrointestinal perforation and that caused by colon perforation, as shown in Table 1. The lack of information regarding the details of the causative diseases in some patients was another limitation of this study. Fourth, the effects of surgical procedures on certain causative disease should be analyzed in a future study.

In conclusion, this report is the first risk stratification study of surgery for ADP to use a nationwide NCD. By analyzing 8,482 patients from 1,285 surgical units throughout Japan, the 30-day and surgical mortality rates were determined to be 9.0 and 14.1 %, respectively. The results of this series are satisfactory regarding the nationwide outcome of surgery for ADP, and this system can be useful in predicting the outcome of surgery for ADP, and may be useful to evaluate and benchmark performance.

Acknowledgments We wish to thank all of the data managers and hospitals that participated in the NCD Project for their efforts in data entry. In addition, we wish to thank Prof. Hideki Hashimoto and Dr. Noboru Motomura for providing direction for the foundation of the NCD, and the working members of the JSGS database committee (Masayuki Watanabe, MD; Satoru Imura, MD; Fumihiko Miura, MD; Hiroya Takeuchi, MD; Ichiro Hirai, MD; Yoshio Takesue, MD; Hiroyuki Suzuki, MD; Megumi Ishiguro, MD; Hiroyuki Konno, MD; Makoto Gega, MD; and Akihiko Horiguchi, MD). This study was partially supported by a research Grant from the Ministry of Health, Labour and Welfare of Japan.

Conflict of interest The authors report no conflicting financial interests.

References

1. Ordoñez CA, Puyana JC. Management of peritonitis in the critically ill patient. *Surg Clin North Am.* 2006;86:1323–49.
2. Blot S, De Waele JJ. Critical issues in the clinical management of complicated intra-abdominal infections. *Drugs.* 2005;65:1611–20.
3. Pieracci FM, Barie PS. Management of severe sepsis of abdominal origin. *Scand J Surg.* 2007;96:184–96.
4. Solomkin JS, Mazuski JE, Bradley JS, Rodvold KA, Goldstein EJ, Baron EJ, et al. Diagnosis and management of complicated intra-abdominal infection in adults and children: guidelines by the Surgical Infection Society and the Infectious Diseases Society of America. *Clin Infect Dis.* 2010;50:133–64.
5. Seiler CA, Brügger L, Forssmann U, Baer HU, Büchler MW. Conservative surgical treatment of diffuse peritonitis. *Surgery.* 2000;127:178–84.
6. Motomura N, Miyata H, Tsukihara H, Takamoto S. Risk model of thoracic aortic surgery in 4707 cases from a nationwide single-race population through a web-based data entry system: the first report of 30-day and 30-day operative outcome risk models for thoracic aortic surgery. *Circulation.* 2008;118(14 Suppl):S153–9.
7. Chen SC, Lin FY, Hsieh YS, Chen WJ. Accuracy of ultrasonography in the diagnosis of peritonitis compared with the clinical impression of the surgeon. *Arch Surg.* 2000;135:170–3.
8. Salem TA, Molloy RG, O'Dwyer PJ. Prospective study on the role of the CT scan in patients with an acute abdomen. *Colorectal Dis.* 2005;7:460–6.
9. Inui T, Haridas M, Claridge JA, Malangoni MA. Mortality for intra-abdominal infection is associated with intrinsic risk factors rather than the source of infection. *Surgery.* 2009;146:654–61.
10. Sartelli M. A focus on intra-abdominal infections. *World J Emerg Surg.* 2010;19(5):9.
11. Horiuchi A, Watanabe Y, Doi T, Sato K, Yukumi S, Yoshida M, et al. Evaluation of prognostic factors and scoring system in colonic perforation. *World J Gastroenterol.* 2007;13:3228–31.
12. Viehl CT, Kraus R, Zürcher M, Ernst T, Oertli D, Kettelhack C. The Acute Physiology and Chronic Health Evaluation II score is helpful in predicting the need of relaparotomies in patients with secondary peritonitis of colorectal origin. *Swiss Med Wkly.* 2012;142:w13640.
13. Rix TE, Bates T. Pre-operative risk scores for the prediction of outcome in elderly people who require emergency surgery. *World J Emerg Surg.* 2007;2:16.
14. Turner PL, Ilano AG, Zhu Y, Johnson SB, Hanna N. ACS-NSQIP criteria are associated with APACHE severity and outcomes in critically ill surgical patients. *J Am Coll Surg.* 2011;212:287–94.
15. Ingraham AM, Cohen ME, Raval MV, et al. Comparison of hospital performance in emergency versus elective general surgery operations at 198 hospitals. *J Am Coll Surg.* 2011;212:2028.
16. Kwok AC, Lipsitz SR, Bader AM, Gawande AA. Are targeted preoperative risk prediction tools more powerful? A test of models for emergency colon surgery in the very elderly. *J Am Coll Surg.* 2011;213:220–5.
17. Ingraham AM, Cohen ME, Bilimoria KY, Ko CY, Nathens AB. Comparison of outcomes after laparoscopic versus open appendectomy for acute appendicitis at 222 ACS NSQIP hospitals. *Surgery.* 2010;148:625–35.
18. Kimura W, Miyata H, Gotoh M, Hirai I, Kenjo A, Kitagawa Y, et al. A pancreaticoduodenectomy risk model derived from 8575 cases from a national single-race population (Japanese) using a web-based data entry system: the 30-day and in-hospital mortality rates for pancreaticoduodenectomy. *Ann Surg.* 2013. (Epub ahead of print).

19. Watanabe M, Miyata H, Gotoh M, Baba H, Kimura W, Tomita N, et al. Total gastrectomy risk model: data from 20,011 Japanese patients in a nationwide internet-based database. *Ann Surg.* (in press).
20. Kobayashi H, Miyata H, Gotoh M, Baba H, Kimura W, Kitagawa Y, et al. Risk model for right hemicolectomy based on 19,070 Japanese patients in the National Clinical Database. *J Gastroenterol.* 2013. (Epub ahead of print).
21. Kenjo A, Miyata H, Gotoh M, Okubo S, Suzuki H, Kitagawa Y, et al. Risk stratification of 7732 hepatectomy cases in 2011 from National Clinical Database for Japan. *J Am Coll Surg.* 2014;218:412–22.
22. Khuri SF. The NSQIP: a new frontier in surgery. *Surgery.* 2005;138:837–43.
23. Miyata H, Hashimoto H, Horiguchi H, Matsuda S, Motomura N, Takamoto S. Performance of in-hospital mortality prediction models for acute hospitalization: hospital standardized mortality ratio in Japan. *BMC Health Serv Res.* 2008;8:229.
24. Riche FC, Dray X, Laisne MJ, Mateo J, Raskine L, Sanson-Le Pors MJ, et al. Factors associated with septic shock and mortality in generalized peritonitis: comparison between community-acquired and postoperative peritonitis. *Crit Care.* 2009;13:R99.
25. Chandra V, Nelson H, Larson DR, Harrington JR. Impact of primary resection on the outcome of patients with perforated diverticulitis. *Arch Surg.* 2004;139:1221–4.
26. Pisanu A, Reccia I, Deplano D, Porru F, Uccheddu A. Factors predicting in-hospital mortality of patients with diffuse peritonitis from perforated colonic diverticulitis. *Ann Ital Chir.* 2012;83:319–24.
27. Welcker K, Lederle J, Schorr M, Siebeck M. Surgery and adjuvant therapy in patients with diffuse peritonitis: cost analysis. *World J Surg.* 2002;26:307–13.
28. Trenti L, Biondo S, Golda T, Monica M, Kreisler E, Fraccalvieri D, et al. Generalized peritonitis due to perforated diverticulitis: Hartmann's procedure or primary anastomosis? *Int J Colorectal Dis.* 2011;26:377–84.
29. Arenal JJ, Bengoechea-Beeby M. Mortality associated with emergency abdominal surgery in the elderly. *Can J Surg.* 2003;46:111–6.
30. Wakefield H, Vaughan-Sarrazin M, Cullen JJ. Influence of obesity on complications and costs after intestinal surgery. *Am J Surg.* 2012;204:434–40.
31. Cook TM, Day CJ. Hospital mortality after urgent and emergency laparotomy in patients aged 65 yr and over. Risk and prediction of risk using multiple logistic regression analysis. *Br J Anaesth.* 1998;80:776–81.
32. Bader FG, Schroder M, Kujath P, Muhl E, Bruch HP, Eckmann C. Diffuse postoperative peritonitis—value of diagnostic parameters and impact of early indication for relaparotomy. *Eur J Med Res.* 2009;14:491–6.
33. Tokuda Y, Abe T, Ishimatsu S, Hinohara S. Ambulance transport of the oldest old in Tokyo: a population-based study. *J Epidemiol.* 2010;20:468–72.
34. Matzen LE, Jepsen DB, Ryg J, Masud T. Functional level at admission is a predictor of survival in older patients admitted to an acute geriatric unit. *BMC Geriatr.* 2012;12:32.
35. Nakazawa A, Nakamura K, Kitamura K, Yoshizawa Y. Association between activities of daily living and mortality among institutionalized elderly adults in Japan. *J Epidemiol.* 2012;22:501–7.